Abstract:Parkinson's disease (PD) is a chronic, progressive neurological disorder affecting approximately 10 million people worldwide, with prevalence expected to rise as the global population ages. It is characterized by the degeneration of dopamine-producing neurons in the substantia nigra pars compacta, leading to motor symptoms such as tremor, rigidity, bradykinesia, postural instability, and gait disturbances, as well as non-motor symptoms including olfactory disturbances, sleep disorders, and depression. Currently, no cure exists for PD, and most available therapies focus on symptom alleviation. This dopamine deficiency impairs motor control, and since dopamine itself cannot cross the blood–brain barrier (BBB), the precursor L-Dopa is commonly used in treatment. L-Dopa is administered with enzyme inhibitors to prevent premature conversion outside the brain, allowing it to cross the BBB and convert to dopamine within the central nervous system. Although these therapies have improved symptom management, recent research has revealed additional molecular factors in PD pathology, such as α-synuclein aggregation, mitochondrial dysfunction, and lysosomal abnormalities, contributing to its complexity. These discoveries open up possibilities for neuroprotective therapies that could slow disease progression. In this review, we categorize PD therapeutic targets into two main groups: currently used therapies and targets under active research. We also introduce promising small-molecule compounds studied between 2019 and 2023, which may represent future treatment options. By examining both established and emerging targets, we aim to highlight effective strategies and potential directions for future drug development in Parkinson's disease therapy.

Recent Advances in Targeting Leucine-Rich Repeat Kinase 2 As a Potential Strategy for the Treatment of Parkinson's Disease.

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease

Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives

Advances in targeted therapies for Parkinson's disease

Leucine-rich Repeat Kinase 2 Inhibitors: a Patent Review (2006 – 2011)

An Update on Potential Therapeutic Strategies for Parkinson’s Disease Based on Pathogenic Mechanisms

Leucine-rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule-associated protein 1B to ameliorate lysosomal dysfunction and parkinsonism

GBA1-and LRRK2-directed treatments: The way forward

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Type-II kinase inhibitors that target Parkinson’s Disease-associated LRRK2

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease

Kinases and Kinase Signaling Pathways: Potential Therapeutic Targets in Parkinson's Disease

The Role of the LRRK2 Gene in Parkinsonism

Identification of LRRK2 Inhibitors Through Computational Drug Repurposing.

Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation

Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets

Characterization of a Selective Inhibitor of the Parkinson’s Disease Kinase LRRK2

LDN-73794 Attenuated LRRK2-Induced Degeneration in a Drosophila Parkinson’s Disease Model

Treating LRRK2-Related Parkinson's Disease by Inhibiting the mTOR Signaling Pathway to Restore Autophagy

Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant Α-Synuclein

Emerging targets and new small molecule therapies in Parkinson’s disease treatment